Algenex, Virbac sign licensing agreement for CrisBio-based vaccine in major swine indication
Algenex SL, a VC-backed biotechnology company delivering disruptive technologies for recombinant biologics production, and Virbac, an animal health company worldwide, have entered into an international licensing agreement for the development and commercialisation of a CrisBio-based vaccine in a major swine indication